Cannabicyclol (R₃=H, R₄=C5H11) | 67920-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: Cannabicyclol (R₃=H, R₄=C5H11)
• 英文别名: cannabicyclol；CBL；Cannabibinol (Cannabicyclol)；9,13,13-trimethyl-5-pentyl-8-oxatetracyclo[7.4.1.02,7.012,14]tetradeca-2,4,6-trien-3-ol
• CAS: 67920-00-7；21366-63-2
• 化学式: C₂₁H₃₀O₂
• 分子量: 314.468
• InChiKey: IGHTZQUIFGUJTG-UHFFFAOYSA-N

物化性质

• 沸点：
  382.1±31.0 °C(Predicted)
• 密度：
  1.068±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (E)-3,7-二甲基-2,6-辛二烯醛 、 3,5-二羟基戊苯 生成 大麻色原烯 、 Cannabicyclol (R₃=H, R₄=C5H11) 、 cannabicitran
  参考文献：
  名称：

  Jochum, Clemens; Gasteiger, Johann; Ugi, Ivar, Angewandte Chemie, 1980, vol. 92, # 7, p. 503 - 513

  摘要：

  DOI：

文献信息

• [EN] CANNABINOID CONTAINING TARGETING LIPOSOMES<br/>[FR] LIPOSOMES DE CIBLAGE CONTENANT DES CANNABINOÏDES
  申请人：NEXTAGE CANNABIS INNOVATION LTD

  公开号：WO2021038574A1

  公开（公告）日：2021-03-04

  Described herein are liposomes containing modified targeting peptides. Liposomes preferably comprise a lipid-based bilayer and at least one cannabinoid. Also provided herein are methods for making the liposomes, and methods for treatment of diseases of the CNS using the liposomes.

  本文描述了含有改良靶向肽的脂质体。脂质体最好包括基于脂质的双层结构和至少一种大麻素。本文还提供了制备脂质体的方法，以及利用脂质体治疗中枢神经系统疾病的方法。
• [EN] LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY<br/>[FR] CONJUGUÉ LIPIDIQUE PRÉPARÉ À PARTIR D'UN FRAGMENT SQUELETTE
  申请人：INTEGRATED NANOTHERAPEUTICS INC

  公开号：WO2020191477A1

  公开（公告）日：2020-10-01

  The application relates to a lipid conjugate of formula M-X1-L wherein M is a molecule of interest such as a drug moiety; X1 is a linker group such as ester, ether or carbamate; and L is a lipid scaffold represented by formula (lId): -L1-[L2(H)(X2R)]n-L3-[L4(H)(X2R)]p-L5-L6 and wherein L comprises 5 to 40 carbon atoms and 0 to 2 carbon-carbon double bonds. The lipid conjugate can be formulated in a drug delivery vehicle such as a lipid nanoparticle (LNP).

  该应用涉及公式M-X1-L的脂质共轭物，其中M是感兴趣的分子，如药物基团；X1是连接基团，如酯、醚或氨基甲酸酯；L是由公式(lId)表示的脂质支架：-L1-[L2(H)(X2R)]n-L3-[L4(H)(X2R)]p-L5-L6，其中L包含5至40个碳原子和0至2个碳-碳双键。该脂质共轭物可以配制在药物传递载体中，如脂质纳米粒子（LNP）。
• Phenyl derivatives and methods of use
  申请人：Dolle E. Roland

  公开号：US20060074086A1

  公开（公告）日：2006-04-06

  Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, and as an appetite stimulant.

  披露了新的苯基化合物、含有这些化合物的药物组合物以及它们的药用方法。在某些实施例中，这些化合物是 cannabinoid 受体的激动剂和/或配体，可能用于治疗和/或预防疼痛、胃肠疾病、泌尿生殖系统疾病、炎症、青光眼、自身免疫疾病、缺血性疾病、免疫相关疾病和神经退行性疾病，用于提供对缺血和再灌注效应的心脏保护，用于诱导恶性细胞的凋亡，以及作为食欲刺激剂。
• [EN] 3BETA-(4-METHOXYBENZYLOXY)PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF CANNABINOIDS-RELATED DISORDERS<br/>[FR] 3BÊTA-(4-MÉTHOXYBENZYLOXY)PREGN-5-ÉN-20-ONE POUR UNE UTILISATION DANS LE TRAITEMENT DE TROUBLES LIÉS AUX CANNABINOÏDES
  申请人：AELIS FARMA

  公开号：WO2019162328A1

  公开（公告）日：2019-08-29

  The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I), for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.

  本发明一般涉及一种特定的孕酮衍生物，用于治疗大麻素相关障碍。更具体地，该发明涉及一种式（I）的化合物，用于治疗大麻素相关障碍。事实上，该发明的化合物在体内对THC的效果具有很强的抑制作用，并且能够抑制THC的非条件和条件效应，包括THC的自我管理以及在非人类灵长类动物中寻求THC的恢复。
• [EN] METHODS FOR EXTRACTION, PROCESSING, AND PURIFICATION OF A SELECTED FAMILY OF TARGET COMPOUNDS FROM CANNABIS<br/>[FR] PROCÉDÉS D'EXTRACTION, DE TRAITEMENT ET DE PURIFICATION D'UNE FAMILLE SÉLECTIONNÉE DE COMPOSÉS CIBLES À PARTIR DE CANNABIS
  申请人：NECTAR HEALTH SCIENCES INC

  公开号：WO2020248077A1

  公开（公告）日：2020-12-17

  Disclosed are methods for separating, recovering, and purifying tetrahydrocannabinolic acid (THCA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids in a selected C5-C7 hydrocarbon solvent, adding thereto a selected amine to thereby precipitate a THCA-amine salt therefrom, dissolving the recovered THCA-amine salt in a selected solvent and then adding thereto a selected antisolvent to thereby recrystallize a purified THCA-amine salt therefrom. The recrystallized THCA-amine salt may be decarboxylated to form a mixture of Δ9-tetrahydrocannabinol (Δ9-THC) and amine. The Δ9-THC amine mixture may be acidified to separate the amine from Δ9-THC. The recovered Δ9-THC may be concentrated to produce a highly purified Δ9-THC. Also disclosed are THCA-amine salts produced with amines selected from groups of diamines, amino alcohols, and tertiary amines.

  揭示了一种从含有大麻酸（THCA）盐的有机溶剂溶液中分离、回收和纯化THCA盐的方法。该方法包括将大麻素混合物溶解在选择的C5-C7烃类溶剂中，加入选择的胺类物质以沉淀出THCA-胺盐，将回收的THCA-胺盐溶解在选择的溶剂中，然后加入选择的抗溶剂以再结晶出纯化的THCA-胺盐。再结晶的THCA-胺盐可以脱羧生成Δ9-四氢大麻酚（Δ9-THC）和胺的混合物。Δ9-THC胺混合物可以酸化以将胺与Δ9-THC分离。回收的Δ9-THC可以浓缩以生产高度纯化的Δ9-THC。还披露了使用二胺、氨基醇和三级胺等胺类物质生产的THCA-胺盐。